MeTA FIP workshop programme

FIP-WHO META Istanbul, Turkey September 5, 2009 1

69th FIP Congress, Istanbul, September 2009

Improving access to medicines:Improving access to medicines:Transparency and Pharmaceutical Transparency and Pharmaceutical

Practice Practice

A workshop co-organised by MeTA A workshop co-organised by MeTA (Medicine Transparence Aliance) and FIP(Medicine Transparence Aliance) and FIP

1


Workshop objectives:Workshop objectives:

1. To inform FIP and interested Congress participants about the Medicines Transparency Alliance (MeTA) and its concept of transparency.

2. To discuss how transparency can be applied in pharmacy practice, especially in developing countries.

3. To strengthen professional links between MeTA and FIP.


TimetableTimetable

09:05-09:15 Opening.09:05-09:15 Opening. Ton HOEK, FIP General SecretaryTon HOEK, FIP General Secretary

09:15-09:30 MeTA and its concept of Transparency : Identification of 09:15-09:30 MeTA and its concept of Transparency : Identification of priority areas. priority areas. W. BANNENBERG, MeTA Technical W. BANNENBERG, MeTA Technical

Director.Director.

09:30-10:00 KEYNOTE SPEECH: 09:30-10:00 KEYNOTE SPEECH: N. LEYESA, Phil.Pharm.Ass.N. LEYESA, Phil.Pharm.Ass.

Transparency and Pharmaceutical Practice in a MeTA Transparency and Pharmaceutical Practice in a MeTA country: The MeTA Philippines country report. country: The MeTA Philippines country report.

10:00-10:20 Group Discussion.10:00-10:20 Group Discussion.

10:20-10:45 Coffee break10:20-10:45 Coffee break

10:45-11:00 Plenary session and Panel discussion.10:45-11:00 Plenary session and Panel discussion.

W. Bannenberg, T. Wuliji; X. Hao Chan; B. Becan,; A. W. Bannenberg, T. Wuliji; X. Hao Chan; B. Becan,; A. Álvarez-Risco; S. Boyaci, M. Bin ShahnaÁlvarez-Risco; S. Boyaci, M. Bin Shahna

11:55-12:00 Summary and closure.11:55-12:00 Summary and closure.




Practice Practice

GROUP AND PLENARY DISCUSSION GROUP AND PLENARY DISCUSSION

4


3 QUESTIONS3 QUESTIONS

Q1:Q1: Is increased transparency Is increased transparency and accountability (e.g. in and accountability (e.g. in pricing, in information on pricing, in information on quality, in disclosure of quality, in disclosure of objective information) objective information) essential to improve access to essential to improve access to medicines?medicines?



Q2:Q2: What are the main What are the main changes to be introduced in changes to be introduced in pharmacy supply chains (from pharmacy supply chains (from manufacture to patient) for manufacture to patient) for them to become more them to become more transparent?transparent?



Q3:Q3: Do we believe good Do we believe good pharmacy practice guidelines pharmacy practice guidelines should include an element of should include an element of transparency and transparency and accountability?accountability?


3 Questions:3 Questions:1.1. Is increased transparency and accountability (e.g. Is increased transparency and accountability (e.g.

in pricing, in information on quality, in disclosure of in pricing, in information on quality, in disclosure of objective information) essential to improve access objective information) essential to improve access to medicines?to medicines?

2.2. What are the main changes to be introduced in What are the main changes to be introduced in pharmacy supply chains (from manufacture to pharmacy supply chains (from manufacture to patient) for them to become more transparent? patient) for them to become more transparent?

3.3. Do we believe good pharmacy practice guidelines Do we believe good pharmacy practice guidelines should include an element of transparency and should include an element of transparency and accountability?accountability?




Practice Practice

Panel Discussion Panel Discussion

9


Panel DiscusionPanel Discusion

Wilbert BANNENBERG, Wilbert BANNENBERG, Technical Director, MeTA.Technical Director, MeTA. Tana WULIJI, Tana WULIJI, Human Resources and Pharmacy Human Resources and Pharmacy

Education, FIP.Education, FIP. Xuan HAO CHAN, Xuan HAO CHAN, Professional and Scientific Affairs, Professional and Scientific Affairs,

Project Officer, FIP.Project Officer, FIP. Bulent BECAN, Bulent BECAN, Turkish Pharma Association of Turkish Pharma Association of

Research Based Companies.Research Based Companies. Aldo ÁLVAREZ RISCO, Aldo ÁLVAREZ RISCO, South American Network of South American Network of

Pharmaceutical care, Peru.Pharmaceutical care, Peru. Serif BOYACI, Serif BOYACI, Turkish Association of Pharmacists.Turkish Association of Pharmacists. Mohamed BIN SHAHNA, Mohamed BIN SHAHNA, WHO.WHO.

Health & Medicine

MeTA FIP workshop programme